After 1- and 6-Month Gains, Gene Editing Companies Await Q3 Results
As developers of gene editing therapies and other genetic medicines get set to report third quarter earnings in…
Sarepta Says Deaths of Two Elevidys Patients Posted on FDA Database Unrelated to Treatment
Sarepta Therapeutics (NASDAQ: SRPT) said Friday that the deaths of two patients taking its marketed gene therapy Elevidys®…